According to a news item this morning on the UKSCblog, which focuses on the activities of the new Supreme Court for the United Kingdom which took over the appellate functions of the House of Lords this autumn, the Supreme Court has refused permission to appeal in Generics (UK) Ltd v Daiichi Pharmaceuticals [2009] EWCA Civ 646 (noted here on The SPC Blog). Generics (now known as Mylan) wanted to appeal against the decision of the Court of Appeal that that Daiichi's by then expired patent antibacterial levofloxacin and the supplementary protection certificate based upon it were valid.
This news item has been picked up by Zenopa here. It does not however appear on the Supreme Court's own website or on any of the usual internet news channels.
A niche blog dedicated to the issues that arise when supplementary protection certificates (SPCs) extend patents beyond their normal life -- and to the respective positions of patent owners, investors, competitors and consumers. The blog also addresses wider issues that may be of interest or use to those involved in the extension of patent rights. You can email The SPC Blog here
Wednesday 18 November 2009
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment